Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Hyderabad-based Dr Reddy’s Laboratories (DRL) has posted a 76 per cent year-on-year (YoY) dip in profit after tax (PAT) to Rs 88 crore in Q4FY22 driven by pricing pressure in North America and Europe, lower export benefits, and an increase in the inventory provisions.

The revenue was up 15 per cent to Rs 5,437 crore for the quarter under review. For the full year, Dr Reddy’s posted a 13 per cent growth in revenues to Rs 21,439 crore, while its net profit was up 37 per cent to Rs 2,357 crore.

Dr Reddy’s stock was trading up 0.74 per cent